Start-up biopharmaceutical company specialized in genitourinary diseases, Ixaltis was born out of the combined expertise of scientists specialized in urology, pharmaceutical experts and experienced managers: Dr. Philippe Lluel, Christian Chavy, Stefano Palea, Dr. Roberto Gradnik and Professors Pascal Rischmann and Xavier Gamé.
Its vision is to develop treatments for genito-urinary tract diseases by identifying drugs having already reached clinical stage and re-explore these for use in genitourinary tract disorders. Ixaltis has established a proprietary position covering Litoxetine for use in urogenital and other disorders based on its specific mechanism of action.
Overall, urinary incontinence affects about 400 million people worldwide and up to 50% of women over 50, with an estimated trend to increase in prevalence. No medical treatment is currently approved for mixed urinary incontinence.
IXALTIS announces successful completion of phase 2 for its lead compound...
Toulouse (31) / Archamps (74), May 14 th , 2019 – Ixaltis is pleased to announce successful completion of the phase 2 of clinical development... read more
Press Release • 14.05.2019 • By IXALTIS